[Clinical experience with ceftibuten in complicated urinary tract infections]. 1990

S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota

Twenty-four patients with complicated urinary tract infections (UTI) were received ceftibuten (CETB) 400 mg b.i.d. orally for 5 days, and the following results were obtained. One of the recipients was excluded for negative bacteriuria before treatment. According to the criteria for evaluation of clinical efficacy of antimicrobial agents on UTI, 23 patients were assessed: 9 of them were judged to show excellent responses, 6 to have moderate responses and 8 poor responses. The overall efficacy was 65%. Four patients with indwelling catheter failed to show positive clinical response, but 15 out of 19 patients without indwelling catheter responded positively. As to bacteriological responses, organisms included Gram-positive cocci were eradicated in 28, replaced in 9 and persisted in 6 strains. Of 24 Gram-negative rods except 1 strain of Pseudomonas sp., 23 (96%) were eradicated. Safety evaluation was made in all 24 patients received CETB. No adverse reactions were observed in any cases. As to laboratory test results, slight, transient elevations of GOT, GPT and Al-P of serum were noted in 1 patient. Their values, however, returned to normal levels in 4 weeks.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077722 Ceftibuten A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections. 7-(2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino)-3-cephem-4-carboxylic acid,7432 S,7432-S,Cedax,SCH 39720,SCH-39720,SCH39720
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
January 1983, The Journal of antimicrobial chemotherapy,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
July 1986, Hinyokika kiyo. Acta urologica Japonica,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
June 1985, Hinyokika kiyo. Acta urologica Japonica,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
March 1976, The Japanese journal of antibiotics,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
March 1976, The Japanese journal of antibiotics,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
September 2001, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
May 1987, Hinyokika kiyo. Acta urologica Japonica,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
December 1989, The Japanese journal of antibiotics,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
July 1965, The Journal of urology,
S Mizutani, and K Nishimura, and K Yoshimura, and S Miyoshi, and N Iwao, and J Higashimoto, and K Shiota
August 1977, The Japanese journal of antibiotics,
Copied contents to your clipboard!